Alder Biopharmaceuticals
Financials
Estimates*
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|---|
Revenues | - | - | 1.0m | - | - | - |
EBITDA | - | - | (288m) | (284m) | (309m) | (255m) |
% EBITDA margin | - | - | (28800 %) | - | - | - |
Profit | - | - | (289m) | (332m) | (313m) | (248m) |
% profit margin | - | - | (28900 %) | - | - | - |
R&D budget | 70.4m | 139m | 230m | 230m | - | - |
R&D % of revenue | - | - | 22990 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$11.0m | Series A | ||
$16.0m | Series B | ||
$40.0m | Series C | ||
$38.0m | Series D | ||
N/A | $200m Valuation: $407m | IPO | |
* | N/A | $230m | Post IPO Equity |
* | N/A | $162m | Post IPO Equity |
$250m | Post IPO Equity | ||
* | N/A | $170m | Post IPO Equity |
$2.0b Valuation: $2.0b -6.9x EV/LTM EBITDA | Acquisition | ||
Total Funding | CAD143m |
Related Content
Recent News about Alder Biopharmaceuticals
EditAlder BioPharmaceuticals, accessible via alderbio.com, is a dynamic startup focused on developing innovative treatments for brain diseases. The company operates in the biopharmaceutical sector, which involves creating drugs and therapies derived from biological sources to treat medical conditions. Alder BioPharmaceuticals primarily serves patients suffering from neurological disorders, including but not limited to migraines and other chronic brain conditions.
The market Alder BioPharmaceuticals operates in is highly specialized and competitive, targeting a global audience with a significant presence in regions such as North America, Europe, and Asia. The company’s business model revolves around extensive research and development (R&D) to discover new treatments, followed by clinical trials to ensure safety and efficacy. Once a treatment is approved by regulatory bodies, Alder BioPharmaceuticals moves to the commercialization phase, where it partners with healthcare providers and pharmaceutical distributors to bring its products to market.
Revenue generation for Alder BioPharmaceuticals primarily comes from the sale of its approved therapies. Additionally, the company may engage in licensing agreements, where it allows other pharmaceutical companies to use its patented technologies in exchange for royalties or upfront payments. This dual approach of direct sales and licensing helps diversify its income streams and mitigate risks associated with drug development.
Alder BioPharmaceuticals is committed to reducing the stigma surrounding brain diseases by sharing true patient stories through its platform, The Lundbeck Magazine. This initiative not only raises awareness but also fosters a supportive community for those affected by neurological conditions.
In summary, Alder BioPharmaceuticals is a forward-thinking company dedicated to improving the lives of patients with brain diseases through innovative treatments and a strong focus on research and development.
Keywords: Biopharmaceuticals, Neurological Disorders, Brain Diseases, Research, Development, Clinical Trials, Commercialization, Licensing, Patient Stories, Global Market.